Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications

Angiogenesis

Volumn 16, Issue 1, 2013, Pages 101-111

  Stahl, Andreas ^a   Stumpp, Michael T ^b   Schlegel, Anja ^b   Ekawardhani, Savira ^b   Lehrling, Christina ^a   Martin, Gottfried ^a   Gulotti Georgieva, Maya ^b   Villemagne, Denis ^b   Forrer, Patrik ^b   Agostini, Hansjürgen T ^a   Binz, H Kaspar ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MOLECULAR PARTNERS AG   (Switzerland)

Author keywords

Binding protein; DARPin; Ophthalmology; Repeat protein; VEGF

Indexed keywords

BEVACIZUMAB; DESIGNED ANKYRIN REPEAT PROTEIN; FLUORESCEIN; RANIBIZUMAB; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL ASSAY; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG BINDING; DRUG CROSS REACTIVITY; DRUG EXTRAVASATION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG RETENTION; DRUG SAFETY; DRUG STABILITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LASER; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; RETINA VASCULAR LEAKAGE; RETINOPATHY; VASCULAR DISEASE;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANKYRIN REPEAT; BLOOD VESSELS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EYE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTRAVITREAL INJECTIONS; MICE; OPHTHALMIC SOLUTIONS; PROTEIN BINDING; RABBITS; RATS; RATS, INBRED BN; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 84871617179     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9302-0     Document Type: Article

References (45)

1. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249-257
2. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-676
3. Carmeliet P, De Smet F, Loges S, Mazzone M (2009) Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 6(6):315-326
4. Marx J (2005) Cancer. Encouraging results for second-generation antiangiogenesis drugs. Science 308(5726):1248-1249
5. Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358(24):2606-2617
6. Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, Kaiser P, Slakter JS, Haller J, Do DV, Mieler WF, Chu K, Yang K, Ingerman A, Vitti RL, Berliner AJ, Cedarbaum JM, Campochiaro PA (2009) A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 116(11):2141-2148 e2141
7. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, Campochiaro PA (2009) Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 116(11):2175-2181 e2171
8. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419-1431
9. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432-1444
10. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27):2805-2816
11. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(1):43-58 e41
12. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prunte C, Schmidt-Erfurth U, Tano Y, Wolf S (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94(1):2-13
13. Hodge W, Brown A, Kymes S, Cruess A, Blackhouse G, Hopkins R, McGahan L, Sharma S, Pan I, Blair J, Vollman D, Morrison A (2010) Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation. Can J Ophthalmol 45(3):223-230
14. Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM (2010) A cost-effectiveness analysis of three treatments for age-related macular degeneration. Retina 30(2):212-221
15. Thiel MA, Coster DJ, Standfield SD, Brereton HM, Mavrangelos C, Zola H, Taylor S, Yusim A, Williams KA (2002) Penetration of engineered antibody fragments into the eye. Clin Exp Immunol 128(1):67-74
16. Ottiger M, Thiel MA, Feige U, Lichtlen P, Urech DM (2009) Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci 50(2):779-786
17. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, Grütter MG, Plückthun A (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22(5):575-582
18. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A (2003) Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 332(2):489-503
19. Kohl A, Binz HK, Forrer P, Stumpp MT, Plückthun A, Grütter MG (2003) Designed to be stable: crystal structure of a consensus ankyrin repeat protein. Proc Natl Acad Sci USA 100(4):1700-1705
20. Wetzel SK, Settanni G, Kenig M, Binz HK, Plückthun A (2008) Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins. J Mol Biol 376(1):241-257
21. Wetzel SK, Ewald C, Settanni G, Jurt S, Plückthun A, Zerbe O (2010) Residue-resolved stability of full-consensus ankyrin repeat proteins probed by NMR. J Mol Biol 402(1):241-258
22. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, Pecorari F, Ward CW, Joos TO, Plückthun A (2007) A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 369(4):1015-1028
23. Steiner D, Forrer P, Plückthun A (2008) Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J Mol Biol 382(5):1211-1227
24. Stumpp MT, Binz HK, Amstutz P (2008) DARPins: a new generation of protein therapeutics. Drug Discov Today 13(15-16):695-701
25. Amstutz P, Koch H, Binz HK, Deuber SA, Plückthun A (2006) Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. Protein Eng Des Sel 19(5):219-229
26. Zahnd C, Pecorari F, Straumann N, Wyler E, Plückthun A (2006) Selection and characterization of Her2 binding-designed ankyrin repeat proteins. J Biol Chem 281(46):35167-35175
27. Korff T, Augustin HG (1999) Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci 112(Pt 19):3249-3258
28. Stahl A, Paschek L, Martin G, Gross NJ, Feltgen N, Hansen LL, Agostini HT (2008) Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett 582(20):3097-3102
29. Stahl A, Paschek L, Martin G, Feltgen N, Hansen LL, Agostini HT (2009) Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol 247(6):767-773
30. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92(23):10457-10461
31. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92(3):905-909
32. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR (1999) Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5(12):1390-1395
33. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46(9):1473-1480
34. Keane PA, Sadda SR (2011) Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab. Clin Ophthalmol 5:771-781
35. Ness T, Feltgen N, Agostini H, Bohringer D, Lubrich B (2010) Toxic vitreitis outbreak after intravitreal injection. Retina 30(2):332-338
36. Leedom AJ, Sullivan AB, Dong B, Lau D, Gronert K (2010) Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury. Am J Pathol 176(1):74-84
37. Bachmann BO, Luetjen-Drecoll E, Bock F, Wiegand SJ, Hos D, Dana R, Kruse FE, Cursiefen C (2009) Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol 93(8):1075-1080
38. Ciulla TA, Criswell MH, Danis RP, Hill TE (2001) Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 119(3):399-404
39. Kawe M, Horn U, Plückthun A (2009) Facile promoter deletion in Escherichia coli in response to leaky expression of very robust and benign proteins from common expression vectors. Microb Cell Fact 8:8
40. Zimmerman T, Petit Frere C, Satzger M, Raba M, Weisbach M, Dohn K, Popp A, Donzeau M (2006) Simultaneous metal chelate affinity purification and endotoxin clearance of recombinant antibody fragments. J Immunol Methods 314(1-2):67-73
41. Kisko K, Brozzo MS, Missimer J, Schleier T, Menzel A, Leppanen VM, Alitalo K, Walzthoeni T, Aebersold R, Ballmer-Hofer K (2011) Structural analysis of vascular endothelial growth factor receptor-2/ligand complexes by small-angle X-ray solution scattering. FASEB J Off Publ Fed Am Soc Exp Biol 25(9):2980-2986
42. Korff T, Augustin HG (1998) Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 143(5):1341-1352
43. Clauss M, Sunderkotter C, Sveinbjornsson B, Hippenstiel S, Willuweit A, Marino M, Haas E, Seljelid R, Scheurich P, Suttorp N, Grell M, Risau W (2001) A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 97(5):1321-1329
44. Siemeister G, Schirner M, Reusch P, Barleon B, Marme D, Martiny-Baron G (1998) An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc Natl Acad Sci USA 95(8):4625-4629
45. Toma HS, Barnett JM, Penn JS, Kim SJ (2010) Improved assessment of laser-induced choroidal neovascularization. Microvasc Res 80(3):295-302